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Abstract 
Autosomal dominant polycystic kidney disease (ADPKD) is an inherited renal disease characterized by 
bilateral renal cyst formation. ADPKD is one of the most common rare disorders, accounting for 
~10% of all patients with end-stage renal disease (ESRD). ADPKD is a chronic disorder in which the 
gradual expansion of cysts that form in a minority of nephrons eventually causes loss of renal function 
due to the compression and degeneration of the surrounding normal parenchyma. Numerous deranged 
pathways were identified in the cyst-lining epithelia leading to the design of potential therapies. 
Several of these potential treatments proved effective in slowing down disease progression in pre-
clinical animal studies, while only one has subsequently been proven to effectively slow down disease 
progression in patients and has recently been approved for therapy in Europe, Canada and Japan. 
Among the affected cellular function and pathways, recent investigations have described metabolic 
derangement in ADPKD as a major trait offering additional opportunities for targeted therapies. In 
particular, increased aerobic glycolysis (the Warburg effect) has been described as a prominent 
feature of ADPKD kidneys and its inhibition using the glucose analogue 2-deoxy-D-glucose (2DG) 
proved effective in slowing down disease progression in preclinical models of the disease. At the 
same time, previous clinical experiences were reported with 2DG showing that this compound is well 
tolerated in humans with minimal and reversible side effects. In this work we review the literature 
and discuss the possibility that 2DG would be a good candidate for a clinical trial in humans affected 
by ADPKD. 
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Brief Overview of ADPKD 
Autosomal dominant polycystic kidney disease (ADPKD) is an inherited renal disease that accounts 
for ~10% of all patients with end-stage renal disease (ESRD) in Europe [1]. Precise prevalence of 
this condition is unknown but according to the main epidemiological studies 3.29 to 3.96 :10.000 
people is the most likely estimated prevalence in Europe [2]. ADPKD is characterised by the 
development of numerous fluid-filled renal cysts that originate in a small proportion (1−2%) of 
nephrons [3,4]. Although cysts develop starting early, due to compensatory hyperfiltration in non-
cystic tubules, renal function decline does not usually become apparent until the fourth or fifth decade 
of life[4]. Progressive cyst formation leads to fibrotic degeneration of the surrounding parenchyma 
including the nephron units not directly affected by cyst formation. This process results in significant 
enlargement of the kidney and in additional symptoms such as pain, hypertension, haematuria, cyst 
and urinary tract infections and ultimately renal failure [4].  
ADPKD is caused by mutations in the PKD1 or PKD2 genes, accounting for approximately 85% and 
15% of cases, respectively [5]. Patients carrying PKD1 mutations, particularly truncating mutations, 
show a faster progression towards loss of renal function as compared to those with inherited PKD2 
mutations. This is reflected in the median age at onset of ESRD being approximately 58 years and 79 
years, respectively [6]. 
ADPKD has been for a long time a condition not susceptible of any specific treatment, but clinically 
manageable only through the control of its many complications. The paradigm has changed radically 
in recent years through the identification of several potential targets for therapy. These have been 
validated on cellular and animal models and in some cases had a translational outcome in small 
controlled pilot studies. Some of these studies have failed validation in medium or large randomized 
trials[7-9], while in at least one case, with the vasopressin antagonist tolvaptan, the process has come 
to the registration in Europe and other countries of the first drug active in ADPKD[10]. 
 4 
In this very focused review, we will highlight recent discoveries pointing to a central role of metabolic 
derangements in the pathogenesis of ADPKD. In particular, we will focus on the role of defective 
glycolysis (the Warburg effect) in ADPKD and in the possibility to target this deregulation by using 
a glucose analogue, 2-deoxy-D-glucose (2DG). We try to collect here all the evidence derived from 
animal studies and from humans that, taken together, define the possibility to use 2DG in clinical 
trials for ADPKD. 
 
Glucose metabolism and the Warburg Effect: Brief overview 
Glucose is the main source of energy for the cells. This simple sugar is metabolized through a 
process named glycolysis (Figure 1). Glucose is transported into the cell by facilitative 
transporters  (GLUT1-4) and phosphorylated in position 6 by the enzyme hexokinase (Hexokinases 
1 or 2, HKs) [11][12]. Eight additional enzymatic reactions take place in the cystosol leading to the 
generation of two pyruvate molecules per glucose molecule[11]. Of all these reactions, three are crucil 
because they are “unidirectional” (Figure 1). In the presence of oxygen, pyruvate is normally 
transported into mitochondria where it is converted into Acetyl-CoA that enters the tricarboxylic acid 
(TCA) to be fully oxydized and to generate approximately 16 molecules of ATP per molecule of 
pyruvate[11],[12] (Oxidative Phosphorylation or OXPHOS, Figure 1).  
In the absence of oxygen, pyruvate is instead converted into lactate in the cytosol (Anaerobic 
glycolysis, Figure 1). In hyperproliferative conditions, such as in the case of cancer, cells tend to use 
this inefficient process, even when oxygen is available[12], for unclear reasons. This pathological 
condition is called “aerobic glycolysis” or the “Warburg effect” and it is one of the hallmarks of 
cancer[12]. Since generation of energy though aerobic glycolysis is much less efficient than oxydative 
phosphorylation (OXPHOS) in mitochondria, cells typically upregulate the entire process of glucose 
import and its cytosolic degradation[12]. The Warburg effect can be often observed also in response 
to defective mitochondrial activity and when other sources of energy fail to fuel mitochondria, such 
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as defective Fatty acids or aminoacids oxidation. Of interest, many different signaling pathwyas can 
drive upregulation of key glyoclyitic enzymes so that, in critical conditions such as Fatty Acids 
Oxidation defects, FAO), cells can upregulate the consumption of glucose and generate the minimal 
energy required for survival and/or proliferation. 
 
Defective Glucose metabolism in ADPKD: evidences from animal models  
Animal models of PKD have proven very helpful over the years in helping translational research 
to both understand the pathophysiology of the human disease and to identify potential new therapies. 
Animal models of PKD range from non-orthologous models (i.e. carrying mutations in genes other 
than the Pkd1 or Pkd2 genes) to the more faithful orthologous models (i.e. those carrying mutations 
in the same genes mutated in humans, Pkd1 and Pkd2).  
Using various models a number of recent studies have suggested that metabolic derangement 
appears to be a key feature of polycystic kidney disease, with some differences reported between 
orthologous and non-orthologous [13-18]. While the non-orthologous models of the disease are 
appropriate models for the ciliopathies in general and could be valuable confirmatory models for 
therapeutic approaches, the recent generation of mice carrying mutations in the Pkd1 and 2 genes 
have become generally accepted as better models to mimick the human condition of ADPKD and 
further investigations should concentrate on these, at least to validate results obtained in non-
orthologous models.  
Previous studies have shown that defective glucose metabolism is a hallmark of ADPKD[14].  In 
particular, it was described that cells, murine PKD kidneys lacking the Pkd1 gene and finally the 
epithelia lining the cysts derived from human specimens tend to rely heavily on glucose as an energy 
source and to convert it into lactate, indicating that they preferentially use anaerobic glycolysis even 
when oxygen is available to them [14]. Subsequent studies on Pkd1 mutant cells have reported 
contradictory results with some studies confirming these original findings [16,19] and some others 
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failing to identify a prominent glycolytic response using cell lines [13,20]. While not all authors 
provided a possible explanation for the inconsistent results, one possibility is that different isolation, 
immortalization and/or culture conditions in cells might be responsible for strongly altering the 
baseline metabolic characteristic of cells, providing a possible explanation. To circumvent this 
possible limitation, Rowe et al. employed metabolic flux analysis in vivo using 13C-labelled glucose 
in orthologous PKD models with a variable degree of severity [14,18]. In all cases it was reported 
that cystic kidneys tend to uptake more glucose and to convert it into lactate [14,18]. Therefore, the 
use of metabolic flux analysis using 13C-labelled molecules could be used as a more accurate way for 
studying the phenomenon in animal models of the disease as widely accepted in other fields and 
possibly allowing to reconcile some of the inconsistencies [14,18].  
Based on these results preclinical studies were designed to test whether interfering with 
glycolysis could have a beneficial effect on disease progression at least in mice. Indeed, 2DG was 
able to revert the glycolytic response in PKD kidneys. Using, again, metabolic flux analysis in vivo 
by co-injecting in the mouse 13C-labelled glucose and 500mg/kg of 2DG [14], it was reported that 
2DG was not able to counteract the increased uptake of glucose as expected [14,18], but was able to 
counteract its conversion into lactate. In addition, 2DG was able to retard disease progression in two 
distinct aggressive models of the disease [14], as well as in slowly progressive PKD model upon 
administration of low doses 2-DG for 2 and half months followed by in vivo analysis of kidney 
volumes [18]. Importantly, a subsequent very detailed study has addressed the role of glycolysis in a 
non-orthologous model of PKD, the Han:Sprd rat [16]. In this case, microarrays analysis of cystic 
versus non cystic kidneys shows a marked signature of increased glycolysis [16] although in vivo flux 
analysis using 13C-labelled glucose was not employed in this case to verify the biological role of this 
transcriptional de-regulation. However, the use of 2DG was proven to be effective in retarding disease 
progression in this study, including improving renal function [16]. Taken together these studies define 
metabolic regulation as a potential important factor in the pathogenesis and/or progression of 
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Polycystic Kidney Disease and as a potential target for therapy 1[14-16,18]. In particular, these 
studies show the efficacy of 2DG in retarding disease progression in preclinical models.   
 
Potential defects in Glucose Handling in ADPKD Patients 
Clinical abnormalities of glucose metabolism in terms of risk of diabetes and glucose intolerance 
have been described in a discrete number of published papers. Most of them have explored the risk 
of new onset diabetes in patients who have undergone kidney transplantation (NODAT): in fact the 
immunosuppressant regimen that transplant receiver is exposed to has an elevated diabetogenic 
potential. The evaluation of this population exposed to an increased diabetogenic state has the 
potential advantage of revealing a mild basal metabolic abnormality due to ADPKD itself. The 
identification of the same abnormality in the general ADPKD population would eventually require a 
much larger sample size to be revealed. The conclusions from the different authors are extremely 
heterogeneous, some of them reporting a positive association between transplantation and NODAT 
[21-29] while others not confirming the association [30-35].  
Recently a metanalysis pooling together twelve of these studies tried to shed some light over the 
ambiguity of this conflicting topic [36]. Even considering the inherent limitations to this approach 
(and in particular the heterogeneity of the collected studies that differ in the definition of the outcome 
and in the ability to report confounders), still it is worth keeping it into account. In fact, the 
metaanalysis suggests a possible increased risk of diabetes in ADPKD; the pooled relative risk (RR) 
for NODAT in patients with ADPKD is statistically significant (RR = 1.92) as compared to those 
who received kidney transplants from other causes. A subanalysis for potential confounders for the 
risk of diabetes (risk adjusted for independent factors of diabetes) showed a significant risk associated 
to ADPKD (RR = 1.98). However, a further subanalysis comprising only studies that collected 
patients requiring insulin treatment could not confirm a significant positive association. In the attempt 
to justify this inconsistency, the authors suggest that the underlying mechanism of ADPKD-related 
NODAT could be insulin resistance, not reduction of insulin secretion. Notably the authors suggest 
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that all the studies had a short follow up and that the development of insulin treatment requirement 
could have needed a longer evaluation. Finally, the missing confirmation of the association because 
of reduction of statistical power (for this analysis 3 of 12 studies were selected) cannot be excluded.  
There are other small-medium sized reports that analyzed insulin secretion [37] and insulin resistance 
[38,39] in nontransplant ADPKD patients with a variable rate of renal function. Data are conflicting 
for insulin resistance and overall insufficient for a conclusive statement for insulin secretion. 
Irrespective of the problem of the increasing risk of diabetes in ADPKD, a case control study 
evaluated the effect of diabetic condition in survival and other clinical characteristics of a cohort of 
ADPKD patients in a longitudinal follow up [40]. ADPKD patients affected by diabetes compared to 
patients without diabetes presented larger kidney and earlier hypertension onset; however renal 
survival was not significantly different between the two groups. 
Considering all these heterogeneous data together a signal of an increased risk for diabetes in ADPKD 
can be suspected. This hypothesis is worth further evaluation in consideration of the potential of 
disclosing new unanticipated pathogenic pathways in this condition. Furthermore this risk is clinically 
relevant and could accordingly suggest modification in the patient management, for example in the 
choice of immunosuppressant regimen in transplant candidates. 
 
Mechanism of activity and safety profile of 2DG in animal models  
Glucose is the principal source of energy for the cell, which metabolizes it through a process named 
glycolysis. Glucose is transported into cells by facilitative transporters  (GLUT1-4) and trapped when 
the enzyme hexokinase (or glucokinase in the liver) phosphorylates it in position 6 [41,11,12]. Eight 
additional enzymatic reactions occur in the cystoplasm leading to generation of two molecules of 
pyruvate [41,11,12] . In the presence of oxygen, the majority of pyruvate is imported into 
mitochondria where it is degraded through the tricarboxylic acid (TCA) to fuel the electron transport 
chain which eventually results in generation of approximately 15 molecules of ATP per molecule of 
pyruvate [41,11,12] .  
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In the absence of oxygen, pyruvate tends to be converted into lactate in the cytosol. In physiological 
conditions this process is called anaerobic glycolysis (also known as the Pasteur effect) and, although 
it is not as effective as the TCA cycle in generating ATP, it ensures cell survival in the absence of 
oxygen [41,11,12]. For reasons that are not fully understood, cancerous cells use this inefficient 
process, even in the presence of oxygen [12]. In this pathological condition the same process of 
pyruvate to lactate conversion is called aerobic glycolysis or the Warburg effect, considered a 
hallmarks of cancer [12]. Since generation of energy through aerobic glycolysis is much less efficient 
than energy production through oxidative phosphorylation in the mitochondria, cells relying on this 
process upregulate glucose import and its cytosolic degradation [12]. Many of the enzymes involved 
in glycolysis are targets of the hypoxia-inducible factor (HIF1), a transcription factor strongly 
upregulated in the absence of oxygen [42]. Reduction of oxygen is not the sole regulator of HIF1 
levels, as the mTORC1 pathway is also able to regulate this molecule [41,42]. the discovery that the 
Warburg effect is observed in PKD opens interesting opportunities including the use of 2DG to slow 
down disease progression as indicated above. 2DG is uptaken by the cells, phosphorylated by 
hexokinase and trapped into the cell, but it cannot be further catabolized. Thus, this compound is in 
fact competing with glucose and preventing PKD mutant cells to use their favorite source of energy 
for proliferation and survival. The strategy had been extensively used in animal models of cancer 
prior to being tested in PKD [14,15,18].  
The Warburg effect in PKD might also offer the opportunity to test additional compounds able to 
inhibit this process in different steps of the glycolytic cascade, a few of which are in phaseII/III 
clinical trials [11]. Thus, in principle, the defective glucose metabolism in PKD might offer additional 
opportunities for intervention besides 2DG, although this compound acts upstream in the very first 
step of the glycolytic cascade and might have several advantages over compounds able to act 
downstream [11]. Finally, it should be mentioned that a recent study has shown that food restriction 
has a great impact and retards the progression of PKD [20]. 2DG has also been considered in the past 
as a calorie restriction mimetic given its capability to reduce metabolic rates in cells, thus it is 
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reasonable to think that food restriction and 2DG likely act through similar mechanisms of action 
[14,20]. 
Several previous studies, including our performed in PKD models, have shown low doses of 2DG do 
not lead to toxicity effects even upon chronic administration [43,44]. It should be considered that a 
single study has shown that chronic prolonged ingestion of high doses of 2DG (250mg/kg/die) caused 
heart vacuolization in the rat [45]. Other studies have reported that chronic intraperitoneal injections 
of even higher doses (500 mg/kg/die) did not cause major toxicity in the rat [43]. Nevertheless the 
single study reporting toxicity has brought some degree of caution about the use of 2DG in humans. 
It should be considered however that subsequent studies in humans have shown that no serious side 
effects could be observed in response to 2DG administration (see below).  
One special consideration should be made with respect to the dosage of 2DG. In a first study high 
doses of 2DG were employed in the mouse (500mg/kg) for only two days and this resulted in a 
significant improvement in the size of the kidney[14]. For these studies, the animals were treated as 
pups at postnatal day 6 to 8. At this stage, animals tend to be very sensitive to any type of treatment 
and some degree of toxicity was observed, including mortality in a few pups both in the wild-type 
and in mutant mice (Chiaravalli, Rowe and Boletta, unpublished). It is hard to determine whether this 
toxicity is specifically due to the use of 2DG or rather due to the delicate nature of newborn animals, 
since treatment of mice at this age also resulted in some degree of mortality irrespectively of the 
molecule used, including metformin and tolvaptan (Chiaravalli, Rowe and Boletta, unpublished).  In 
all cases, subsequent studies in the adult showed that animals treated with even very high doses of 
2DG (500mg/kg) do not show any type of suffering [16,43]. Furthermore, when 2DG was used for 
2.5 months in a slowly progressive model of PKD at a dosage of 100mg/kg/die for 5 days a week, no 
signs of toxicity were found [18]. A thorough histological and biochemical analysis of these animals 
revealed no signs of toxicity. Furthermore, behavioral studies further showed no evidence of toxicity 
of this compound. This is encouraging because based on the human equivalent dose [46] 100mg/kg 
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in the mouse correspond to approximately 8,1mg/kg in the human and this dose is several folds lower 
than the described tolerated dose of 63 mg/kg according to previous clinical trials (see below). 
 
Clinical studies safety profile of 2DG in humans   
A wide range of possible clinical indications has been proposed for 2DG. Among the most 
consistently reported in literature there are antiviral activity, caloric restriction activity and 
antineoplastic activity. Despite the increasing number of in vitro and preclinical reports for a wide 
group of indications, few human clinical trials have been published and these are exclusively related 
to the antineoplastic activity of 2DG [47-50]. 
 The antiviral effect of 2-DG has been demonstrated in vitro against a variety of enveloped viruses 
[51-54]. Viruses dramatically modify cellular metabolism in the attempt to optimize their efficiency 
of replication. Virus-induced metabolism may provide increased pools of free nucleotides necessary 
for rapid viral genome replication as well as increased amino acid production for rapid virion 
assembly, lipid material may be needed to provide material for envelopment of the viral particles. 
Adjustments to metabolic pathways may be required to provide ATP in a rapid fashion for the high 
energy cost of replication. Despite of the interest in 2DG as antiviral agent and many publications of 
in vitro inhibition, clinical data regarding this strategy are not publicly available at this time 
[54,53,52]. 
2DG also has been proposed as a possible caloric restriction mimetic. Reduction in calorie intake 
produces a significant extension of both mean and maximal lifespan in laboratory rodents; this effect 
has been unambiguously reproduced in a number of different animal models and confirmed in 
nonhuman primates [55]. Because of this strong effect and high difficulty in adopting a stringent 
caloric regimen in the clinical setting, there is a significant interest in the pharmacological approach 
of caloric restriction mimetics and 2DG is a good candidate. Interestingly 2DG showed the ability to 
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extend lifespan in a nematode model [56], however rodents data are not conclusive yet 
[45,57,43,58,59] while human studies are not available. 
 
The transition to aerobic glycolysis is advantageous to cancer cells because it confers to them a 
survival and proliferative advantage. While the general view is widely accepted by the scientific 
community, details and precise cellular mechanisms of aerobic glycolysis and its induction are elusive 
and still controversial [60-62,11]. Although aerobic glycolysis represents a replicative advantage, at 
the same time this could turn into weakness for neoplastic cells and indeed a therapeutic opportunity: 
in fact, at least some tumor types become almost completely dependent on the glycolytic pathway for 
their energetic need and inhibiting this process may obtain the death of the cancer cell itself. Although 
the Warburg effect is not completely applicable to all cancers, this phenomenon is a largely prevalent 
process between many neoplasms [60]. Accordingly the glucose analog 2-Deoxy-D-glucose (2DG) 
theoretically is a promising treatment for many cancers, either by itself, or in combination with 
radiotherapy or chemotherapy [63]. 
The first documentation of the use of 2DG in a human treatment was reported in 1958 in five patients 
affected by different type of malignancies (islet cell carcinoma, acute myeloid leukemia, chronic 
lymphocytic leukemia, acute lymphocytic leukemia, bronchogenic carcinoma)[50]. 2DG was 
administered intravenously and orally at dosage that ranged from 50 to 200 mg/kg. The authors 
described that the patients tolerated well the treatment with the exception of episodes of drowsiness, 
facial flush, diaphoresis, warmth that could be promptly reversed by glucose infusion. In one woman 
affected by acute myeloid leukemia tachycardia was recorded and the ECG showed premature 
ventricular beats that were not appreciated in a previous exam. In this study, all the patients developed 
hyperglycemia during infusion or oral administration of 2DG.  
The first clinical experience of 2DG in a group of healthy subjects is reported in an American study 
in 1961. In this study 11 patients were tested to study the metabolic parameters related to plasma 
levels of free fatty acids, glucose and lactate [50]. 
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Two studies in the 70s  evaluated the 2DG as pharmacologic assessment of the procedure success in 
patients having undergone to surgical vagotomy [64,65]. The two studies report a case series of 85 
patients of which 75 were investigated with continuous ECG (see below for further details). Subjects 
were administered a 60 mg / kg oral dose of 2DG, with the exception of two subjects that were treated 
by 50 mg/kg and 70 mg/kg respectively. The authors declared that in no case there were symptoms 
that advised discontinuation of the protocol. The reported symptoms were related to a hypoglycemic-
like condition (drowsiness, hunger, sweating) and were rapidly reversible with the administration of 
glucose. 
More recently another Clinical Trial about the use of 2DG was published in 2005 and evaluated the 
use of inhibition of glycolysis associated to radiotherapy in glioblastoma [49]. In this setting the 
driving idea is to enhance the efficacy of radiotherapy by selectively sensitizing cancer cells by 2DG. 
In this trial an escalating 2-DG dose during combined treatment (2-DG and radiotherapy) has been 
tested in untreated patients with histologically proven glioblastoma multiforme. Escalating 2-DG 
doses (200–250–300 mg/kg BW) were administered orally 30 min before irradiation after overnight 
fasting. The treatment was well tolerated at 2DG dosage up to 250 mg/kg. At the highest dosage (300 
mg/k) two out of six patients experienced restlessness and could not complete the protocol. However 
even at the lower dosage (that was any way a relatively high dosage if compared to other neoplastic 
trials of 2DG) most of the patients referred symptoms resembling hypoglycemia. The discontinuous 
high dosage of 2DG used in this trial addresses the need of an acute treatment strategy for sensitization 
of cancer cells before radiotherapy: this therapeutic regimen has a different rationale compared to the 
aim of a continuous and chronic inhibition of cystogenesis that was adopted in preclinical experience 
of 2DG in the mouse ADPKD model [18,14].  
A later study evaluated the use of 2DG in patients affected by prostatic cancer (9 patients) and other 
solid tumors (3 patients: nasopharynx, lung and cervix cancer). In this study an escalating approach 
has been adopted to evaluate the maximum tolerated dosage. This trial collected some interesting data 
about pharmacokinetics, FDG-PET imaging as a marker of drug uptake and p62 protein levels as 
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markers of autophagy. The starting dose for this study was 30mg/kg of 2DG administered orally on 
a daily schedule for 2 weeks (days 1–14) of a 3-week (21 days) cycle. During the study dose levels 
were increased from 30 to 45, and 60 mg/kg. The authors considered the dose of 45 mg/kg as the 
recommended dose for future phase II trials. The dose was chosen because of two patients that 
experienced a dose-limiting toxicity of grade 3 (asymptomatic QTc prolongation) at the dose of 60 
mg/kg. The authors reported that none of the 5 patients treated at the dose of 45 mg/kg experienced 
any dose limiting toxicity or electrocardiac abnormality; fatigue and dizziness were the prevalent 
adverse events in these patients. The nature of the alteration of cardiac electrophysiology is not clear 
but could be related to myocardial toxicity. A toxicity of this nature has been reported in rats treated 
at high dose of 2DG [45], in humans two previous reports of prolonged QT interval were described 
in the already cited studies of 2DG stimulation of gastric acid production[64,65]. 
In these studies 75 patients (27 in the first report[65] and 48 in the second[64]) were recruited and 
exposed to 2DG. A group of these patients developed non-specific T wave flattening and QT 
prolongation, without any event of serious arrhythmias [64,65].  
The late available study of 2DG in humans was published in 2013 and reports the result of an 
association regimen of 2DG and docetaxel, an anti-mitotic chemotherapy approved for treatment of 
locally advanced or metastatic breast cancer, head and neck cancer, gastric cancer, hormone-
refractory prostate cancer and non small-cell lung cancer. In this study the authors applied a modified 
accelerated titration design to evaluate the maximum tolerated dosage (MTD) of 2DG. Notably the 
MTD was not formally defined in this study because patient did not experience any dose limiting 
toxicity specified by the protocol. Based on the overall tolerability of the treatment the authors 
suggested a 2DG dosage of 63 mg/kg in phase II trials. In fact starting from this dose and at the higher 
dose of 88 mg/kg patients presented plasma glucose levels above 300 mg/dL and symptoms of 
glucopenia (sweating, confusion, weakness and dizziness). Other significant adverse effects recorded 
during the trial at 63-88 mg/kg doses were gastrointestinal bleeding (6 %) and reversible grade 3 QTc 
prolongation (22 %). After the end of the study one patient died from a serious adverse event of 
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cardiac arrest 17 days after the last dose of 2DG. Final ECG done 10 days before death showed 
persistent T-wave inversion and no QTc prolongation. However, it should be noted that the eligibility 
criteria of patients in this study with advanced or metastatic solid tumors could have played a 
confounding role in relation to survival. 
 
Concluding remarks  
Unexpectedly metabolic deregulation has become an important key to understanding the 
pathophysiology of ADPKD. As previously reported, qualitatively suboptimal but converging data 
are available on a possible increased risk of insulin resistance in ADPKD patients. In parallel, widely 
replicated data in a large majority of independent research groups have recognized in animal models 
a profound metabolic derangement and in particular an increased glucose avidity by cystic cells 
(Warburg effect). Finally the metabolic interference by a known inhibitor of glycolysis, 2DG, has 
demonstrated in multiple animal models the ability of slowing the progression of cystic disease. All 
these elements suggest that this metabolic pathway may be a rational therapeutic target. The 2DG is 
a molecule for which a discrete previous clinical experience is provided. The demonstrated efficacy 
in murine models and apparent good tolerability profile in earlier clinical trials pose this molecule as 
the natural candidate in a pilot clinical trial. Nevertheless, other molecules that insist on the same 
metabolic pathway and in advanced stages of drug development are placed in a very interesting 
position in future therapeutic approach of ADPKD. 
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 Singh D et al. 2005[49] Stein M et al. 2010[48] Raez LE et al 2013[47] 
Phase 
I I I 
Disease 
glioblastoma multiforme Prostate Cancer or other 
solid tumor 
Advanced Solid Tumor 
Patients 
12 12 34 
Dose 
200–250–300 mg/kg 30 – 45 – 60 mg/kg Uptitration from 2 mg /kg to  
88 mg /kg 
Treatment 
Regimen and 
Duration 
7 administr. ; 1 per week Daily admin. for  2 wks 
/on a 3 wks cycle;  6 weeks 
7 daily doses during weeks 1 
and 3 of every 4-week cycle; 
(Docetaxel on day 1 of weeks 
2, 3 and 4) ; duration 16 
weeks 
Toxicity 
Excess sweating, 
transient disorientation, 
restlessness , vomit, 
headache 
fatigue, QTc prolongation hyperglicemia, excess 
sweating, disorientation, 
fatigue, gastric bleeding, QTc 
prolongation, 1 death 
Table 1: main charecteristics and data of published clinical trial of 2DG 
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